|View printer-friendly version|
|January 26, 2005 9:52 a.m.|
|Teva Announces Global In-Market Fourth Quarter Sales Of Copaxone® Increased 26% To $261 Million|
Annual Sales Increased 30% To Record $936 Million
Jerusalem, Israel, January 26, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached $261 million in the fourth quarter ended December 31, 2004, an increase of 26% over the comparable quarter of 2003. For the full year 2004, global in-market sales of Copaxone® reached an all-time high of $936 million, an increase of 30% over 2003.